Key Highlights
- Revenue was USD 48.84 million against an estimate of USD 59.23 million.
- Diluted loss per share was USD 0.18 against an estimate of USD 0.07.
- Net product Revenue was USD 48.74 million, against USD 31.78 million.
- Net loss was USD 184.57 million, against USD 67.27 million.
ImmunityBio (NASDAQ:IBRX) reported third quarter 2026 revenue of USD 48.84 million, against an estimate of USD 59.23 million. The diluted loss per share was USD 0.18, compared with an estimate of a USD 0.07 loss and a USD 0.07 loss in the third quarter of 2025. Basic loss per share was USD 0.17.
Net loss was USD 184.57 million, compared with USD 67.27 million a year earlier. The loss from operations was USD 77.99 million, against USD 55.63 million. The company presents these figures in its condensed consolidated statements of operations for the three and nine months ended September 30, 2026.
Product Revenue and Costs
Net product revenue was USD 48.74 million, compared with USD 31.78 million, an increase of USD 17.0 million due to an increase in sales of ANKTIVA. Other revenues decreased USD 0.2 million, primarily due to decreased bioreactor and related consumable product sales and decreased license Royalty income.
Cost of sales increased USD 1.1 million, primarily due to an increase in inventory write-offs and other costs. Research and Development expense was USD 68.96 million, against USD 48.66 million, an increase of USD 20.3 million. Selling, general and administrative expense was USD 52.49 million, against USD 35.51 million.
Nine-Month Results
Total operating costs and expenses were USD 126.83 million for the quarter, against USD 87.69 million, and USD 353.76 million for the nine months, against USD 266.35 million. Nine-month product revenue was USD 143.58 million, against USD 74.71 million.
Net loss for the nine months was USD 1.05 billion, compared with USD 289.51 million, and the loss per share was USD 1.00, against USD 0.32. The loss from operations for the nine months was USD 209.48 million, against USD 191.34 million.
Liquidity and Going Concern
Cash and cash equivalents were USD 45.08 million at September 30, 2026, against USD 88.33 million, and marketable securities were USD 289.25 million, against USD 154.48 million. The filing states that substantial doubt exists regarding the company's ability to continue as a Going Concern without additional funding or financial support.
The filing states that the company began capitalizing inventory costs for ANKTIVA after receiving FDA approval in April 2024, and its forward-looking statements reference commercializing ANKTIVA globally in current and future approved indications, including NMIBC and NSCLC.
The company received net proceeds of USD 28.5 million and USD 175.6 million from its at-the-market program during the three and nine months ended September 30, 2026. It also states that it anticipates needing additional financing to fund operations, complete commercialization of its approved product and conduct clinical trials.
ImmunityBio Q3 2026 Earnings: Key Takeaways
ImmunityBio reported third quarter 2026 revenue of USD 48.84 million and a diluted loss per share of USD 0.18. Net product revenue was USD 48.74 million, net loss was USD 184.57 million, and the filing includes a going concern disclosure.
_11_16_2026_19_56_26_124029.jpg)





Please wait processing your request...